Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver
Phase 1
Completed
- Conditions
- Hepatobiliary DisordersNon-alcoholic Fatty Liver Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 67
- Registration Number
- NCT03357380
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity
Phase 1
Completed
- Conditions
- Metabolism and Nutrition DisorderObesity
- Interventions
- Drug: NNC9204-1177 A 1.0 mg/mLDrug: PLACEBO
- First Posted Date
- 2017-10-12
- Last Posted Date
- 2021-12-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 99
- Registration Number
- NCT03308721
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Overland Park, Kansas, United States
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT03292185
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China
A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- Drug: Placebo (semaglutide 1.0 mg)Drug: Placebo (semaglutide 0.5 mg)
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2021-02-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT03288740
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, China
Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2017-08-31
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1264
- Registration Number
- NCT03268005
- Locations
- 🇺🇦
Novo Nordisk Investigational Site, Vinnytsia, Ukraine
Awareness, Care and Treatment in Obesity Management
Completed
- Conditions
- Metabolism and Nutrition DisorderObesity
- Interventions
- Other: No treatment given
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2019-07-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2545
- Registration Number
- NCT03235102
- Locations
- 🇨🇦
Novo Nordisk Investigational Site, Edmonton, Alberta, Canada
Awareness, Care & Treatment in Obesity Management (ACTION) Study
Completed
- Conditions
- Metabolism and Nutrition DisorderObesity
- Interventions
- Other: No treatment given
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2019-07-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3767
- Registration Number
- NCT03223493
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Honeoye Falls, New York, United States
Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Drug: NPH insulin
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 752
- Registration Number
- NCT03220425
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, York, United Kingdom
A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- Interventions
- First Posted Date
- 2017-07-12
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 58
- Registration Number
- NCT03215498
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.
Phase 1
Completed
- Conditions
- Growth Hormone DisorderAdult Growth Hormone DeficiencyGrowth Hormone Deficiency in Children
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2019-05-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 34
- Registration Number
- NCT03212131
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia
© Copyright 2025. All Rights Reserved by MedPath